Biocon to further develop insulin Tregopil
Advertisement
New Delhi: Biotechnology major Biocon said that phase-I clinical studies conducted in the US for insulin Tregopil have yielded positive results and shows that oral delivery of insulin is feasible.
Commenting on the data, Biocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a unique oral insulin."
Based on the positive data, Biocon has decided to take this research asset into next phase of clinical trials for validation in a larger patient cohort, the company said in a regulatory filing.
"Two major complications of current insulin treatments, hypoglycemia and weight gain, could be potentially minimised by treatment with insulin Tregopil," Biocon Clinical Advisory Board member Harold Lebovitz said.
"Insulin Tregopil has the potential for more rapid insulisation of the liver and a significantly lower propensity to cause postprandial hypoglycemia then insulin Aspart," Biocon said.
Commenting on the data, Biocon CMD Kiran Mazumdar-Shaw said: "The data is extremely promising and based on what we know today Tregopil may be positioned as a unique oral insulin."
Based on the positive data, Biocon has decided to take this research asset into next phase of clinical trials for validation in a larger patient cohort, the company said in a regulatory filing.
"Two major complications of current insulin treatments, hypoglycemia and weight gain, could be potentially minimised by treatment with insulin Tregopil," Biocon Clinical Advisory Board member Harold Lebovitz said.
"Insulin Tregopil has the potential for more rapid insulisation of the liver and a significantly lower propensity to cause postprandial hypoglycemia then insulin Aspart," Biocon said.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.